RxDoctor Payments Data

Michael Cannaday, MD

Internal Medicine · Washington, DCNPI 1851472781

Payments from drug & device makers

$5,064in general payments, 2019–2025

Across 257 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Boehringer Ingelheim$714
  • Lilly USA, LLC$489
  • AstraZeneca$369
  • Astellas Pharma US Inc$361
  • Pfizer$335
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,96498%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,064 in reported general payments places this provider in the 90th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$350,029
Medicare patients
522
Services billed
5,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$150,263
JardianceEmpagliflozin69$69,030
JanuviaSitagliptin Phosphate49$50,209
JanumetSitagliptin Phos/Metformin Hcl51$41,886
MounjaroTirzepatide21$29,725
XareltoRivaroxaban22$26,034
OzempicSemaglutide15$25,756
MyrbetriqMirabegron31$19,467
LinzessLinaclotide12$16,469
EntrestoSacubitril/Valsartan11$13,923
TradjentaLinagliptin12$13,302
MultaqDronedarone Hcl13$10,686
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro12$6,750
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid26$6,728
Colchicine41$6,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$335$150,263152 claims
MerckJanuvia, Janumet, Belsomra$99$97,376116 claims
Boehringer IngelheimJardiance, Tradjenta$714$82,33281 claims
Lilly USA, LLCMounjaro$489$29,72521 claims
Johnson & JohnsonXarelto$32$26,03422 claims
Novo NordiskOzempic$1,308$25,75615 claims
Astellas Pharma US IncMyrbetriq$361$19,46731 claims
AbbVieLinzess, Synthroid$84$18,70952 claims
NovartisEntresto$174$13,92311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →